Health and Finance｜Neptunus Biotech's application for fixed increase passed the review of Feihe e-commerce business scope to add health care products retail

Original title: Kang·Cai｜Neptunus Biotech's application for fixed increase passed the review of Feihe e-commerce business scope to add health care products retail

Neptunus Biotech's application for non-public issuance of shares was approved

Neptunus Biotech's application for non-public issuance of shares was approved

On February 22, Neptunus Bio-engineering issued an announcement stating that the Issuance Review Committee of China Securities Regulatory Commission had reviewed Shenzhen Neptunus Bio-Engineering Co.

On February 22, Neptunus Bio-engineering issued an announcement stating that the Issuance Review Committee of China Securities Regulatory Commission had reviewed Shenzhen Neptunus Bio-Engineering Co.

Feihe e-commerce company's business scope adds health care product retail

2 On May 22, the day the investigation was informed eye, Heilongjiang American power -commerce Co.

2 On May 22, the day the investigation was informed eye, Heilongjiang American power -commerce Co.

People's Tongtai: Chen Weizhong, Chairman of the Board of Supervisors, leaves office

On February 22, Harbin Pharmaceutical Group People's Tongtai Pharmaceutical Co.

On February 22, Harbin Pharmaceutical Group People's Tongtai Pharmaceutical Co.

JD.

February 15th, financial industry news: During this year's Jingdong New Year's Day, the consumption of health products has grown rapidly, and gift-boxed health products are especially popular among users.

Yiling Pharmaceutical: The market demand for Lianhua Qingwen has increased significantly recently

On February 21, Yiling Pharmaceuticals stated on the interactive platform that the market demand for Lianhua Qingwen has increased significantly recently, not only in medium- and high-risk areas, but also in provinces and cities in other low-risk areas.

On February 21, Yiling Pharmaceuticals stated on the interactive platform that the market demand for Lianhua Qingwen has increased significantly recently, not only in medium- and high-risk areas, but also in provinces and cities in other low-risk areas.
Lianhua Qingwen is experiencing colds and flu.
Market demand has also increased compared with previous years.
At present, the sales situation of Lianhua Qingwen products is relatively good, and the company is making every effort to produce to ensure market supply.
At the same time, the company's cardiovascular and cerebrovascular products have a relatively good sales momentum this year.